[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$foazrVwWD6l1suTXiEsWJMRVtPVfPtsEvAqSMueF2BSc":8,"$fCkfvIl3rUsQiBotRWvRZVY78_IMezQR068nGkcu-BDs":55,"$fEtMNaHjKKQ5bwFl9XM7ooodrCT_TFXv1rMBjjArvZ1o":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},68213,867283,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//o1oe1SwU3vlGsqy95secRlqRH2wkEV8k.png","王俊","烟台高新技术产业开发区医院","普通内科","主治医师",416,0,"肺癌IIIB期常用药品用药指南：实用安全细节全解析 🚩","","https://ystcdn.venuertc.com/venue/AI/fb6d53f7-036e-4ec3-b915-9df8958214d5.jpg","\u003Cdiv class=\"lcg2-materials-outer\">\n  \u003Ch1 id=\"material_title\" class=\"lcg2-title-main\">\n    肺癌IIIB期常用药品用药指南：实用安全细节全解析 🚩\n  \u003C/h1>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">什么药品常用于肺癌IIIB期的治疗？\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      肺癌IIIB期相关治疗药品主要分为以下几大类：\u003Cstrong>化疗药物\u003C/strong>（如顺铂、培美曲塞）、\u003Cstrong>靶向药物\u003C/strong>（如吉非替尼、厄洛替尼、奥希替尼）、\u003Cstrong>免疫检查点抑制剂\u003C/strong>（如帕博利珠单抗）以及必要的\u003Cstrong>辅助药物\u003C/strong>（止吐药、护胃药等）。这类药物在用药前、中、后都需要关注不同的细节，掌握关键点才能发挥最大疗效，同时减少风险。本文将带你系统了解这几类常用药品在实际使用中的具体要点，覆盖7个核心细节，每一点都关乎安全和效果。\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">1. 化疗药物：剂型特点及正确用法\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      化疗常用的药品包括顺铂、培美曲塞等，主要为注射剂型。\u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>这类药物必须由专业医疗人员在医院静脉注射，避免在家自行使用。\u003C/li>\n        \u003Cli>化疗用药一般按疗程分周期使用，不能自行增加或减少剂量；每次治疗前需体检评估身体状况。\u003C/li>\n        \u003Cli>静脉注射过程中要严密观察有无局部肿胀、红痛等异常，如出现及时告知护士。\u003C/li>\n        \u003Cli>部分化疗药（如顺铂）需大量补液，防止肾脏负担加重。\u003C/li>\n        \u003Cli>部分药物配合抗吐药、护胃药一同给药，以减轻恶心、胃黏膜损伤等不良反应。\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">案例参考：\u003C/span>“有位患者在接受顺铂化疗时，严格遵医嘱补液，明显减少了肾功能的急性损伤概率。”\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">2. 靶向药物：常见种类与服药时间\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      靶向药物如吉非替尼、厄洛替尼、奥希替尼为口服片剂，部分适合EGFR等基因特征人群。\u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>通常每日一次，建议在固定时间服用，有助于维持药效稳定\u003C/li>\n        \u003Cli>吉非替尼、奥希替尼可餐前或餐后服用，但最好避开高脂油腻食物\u003C/li>\n        \u003Cli>厄洛替尼通常要求空腹服用，与进食间隔至少1小时以上，提前准备更妥当\u003C/li>\n        \u003Cli>服药时整片吞服，不得掰碎、咀嚼或溶解，影响药效\u003C/li>\n        \u003Cli>用200ml温水送服，避免柚子汁或葡萄汁同服，以免增强副作用\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">数据表明：\u003C/span>“厄洛替尼在空腹状态下吸收率最高，随餐服用可能使吸收量增加或不稳定。”\u003Cspan class=\"lcg2-cite\">（Shepherd et al., J Clin Oncol, 2005）\u003C/span>\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">3. 免疫检查点抑制剂：使用细节与用药禁忌\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      PD-1/PD-L1类药物如帕博利珠单抗，多为注射剂型，用于部分耐药或特殊人群。\u003Cbr>\n      \u003Cstrong>正确做法：\u003C/strong>\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>必须在医院专业医生指导下给药，1次/2周或1次/3周静脉点滴\u003C/li>\n        \u003Cli>治疗期间须定期检查肝肾功能、甲状腺激素以及免疫指标\u003C/li>\n        \u003Cli>有免疫系统疾病、活动性感染者禁用\u003C/li>\n        \u003Cli>用药后如出现发热、疲乏、皮疹或其他全身不适，需及时联系医生\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">临床研究：\u003C/span>“严重免疫相关不良反应（如皮肤炎、肠炎）发生率约10-15%，及时发现可降低风险。”\u003Cspan class=\"lcg2-cite\">（Gettinger et al., Lancet Oncol, 2016）\u003C/span>\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">4. 辅助用药：如何配合减轻不良反应\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      化疗及靶向用药期间，常用止吐药（如昂丹司琼）、护胃药（如奥美拉唑）和部分护肝药等，辅助预防或减轻不良反应。\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>止吐药多在化疗当天及之后服用，按医嘱定时服用，不要随意自行延长\u003C/li>\n        \u003Cli>护胃药如奥美拉唑一般空腹服药，可减少胃酸分泌，需整片吞服\u003C/li>\n        \u003Cli>使用护肝药时要定期复查肝功能，通过调整用药方案来保护肝脏\u003C/li>\n        \u003Cli>辅助用药总体安全性较高，如用药后出现皮疹、腹泻等不良反应，应与医生沟通调整\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">用药经验：\u003C/span>“在使用奥美拉唑保护胃黏膜期间，偶有患者出现轻微腹胀，通常不必特殊处理。”\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">5. 不良反应及其应对\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      常见不良反应依药品种类有所不同。化疗药较多见白细胞下降、肝肾损伤，靶向药或免疫制剂较多见皮疹、腹泻、关节不适。\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>大部分轻度不良反应可通过休息和调整饮食缓解，必要时与主治医生沟通调整方案\u003C/li>\n        \u003Cli>如用药后出现明显皮疹、腹泻、血尿、持续高烧等情况，应立即就医\u003C/li>\n        \u003Cli>持续性口腔溃疡、手足麻木等需注意可能为药物不良反应，不应自行停药\u003C/li>\n        \u003Cli>免疫抑制药用药期间需警惕感染征象，任何异常体温都应监测\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">研究数据：\u003C/span>“靶向药物相关皮疹发生率在45%左右，出现后用低剂量糖皮质激素可有效缓解。”\u003Cspan class=\"lcg2-cite\">（Lacouture et al., Oncologist, 2009）\u003C/span>\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">6. 药物相互作用：避免哪些常见误区？\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      多种药物联合使用时，药物间的相互作用会影响疗效及安全性。\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>服用靶向药时应避免同时服用酮康唑、利福平等影响肝酶的药品，否则药物浓度易异常波动\u003C/li>\n        \u003Cli>部分抗生素与顺铂合用可增加肾脏毒性，用药前务必告知所有用药清单\u003C/li>\n        \u003Cli>靶向药和奥美拉唑等PPI制剂合用，可能影响吸收，谨遵医嘱安排服药时间\u003C/li>\n        \u003Cli>中成药或补品同服前须向医生核对，部分中药会加剧肝肾负担或产生不良反应\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">特别提醒：\u003C/span>“同时服用葡萄柚或相关果汁可能增强吉非替尼的血药浓度，增大不良反应风险。”\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-subtitle-bg\">\n    \u003Ch2 class=\"lcg2-subtitle\">7. 储存方法与用药提醒\u003C/h2>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-section\">\n    \u003Cp>\n      正确储存药品能够确保药效不减低，减少变质风险：\n      \u003Cul class=\"lcg2-list\">\n        \u003Cli>绝大多数化疗、靶向药需避光避湿，常温（20-25℃）储存，防止高温或冰冻\u003C/li>\n        \u003Cli>部分生物制品类药物（如PD-1抑制剂）需2-8℃冷藏，不能冷冻\u003C/li>\n        \u003Cli>开封后的药瓶、片剂需避开孩童和宠物，防止误食\u003C/li>\n        \u003Cli>出行时药品可分装于原包装药盒，并随身携带用药说明，便于核查和补充\u003C/li>\n        \u003Cli>过期药品务必按照药店或社区卫生机构建议妥善处理，禁止随意丢弃\u003C/li>\n      \u003C/ul>\n      \u003Cspan class=\"lcg2-highlight\">小贴士：\u003C/span>“药品变色、变味、受潮后禁止继续服用，用前请认真核对有效期。”\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-summary\">\n    \u003Ch3 class=\"lcg2-summary-title\">结语：安全用药，是每次用药的底线！\u003C/h3>\n    \u003Cp>\n    用于肺癌IIIB期的相关药品，无论是化疗、靶向还是辅助药物，都有各自独立的使用细则。请记住：\u003Cspan class=\"lcg2-summary-highlight\">规范服用、警惕相互作用、重视储存条件、出现不良反应立刻寻医\u003C/span>，是安全用药的基石。每位患者与家属都可以把上面的七点贴在药盒旁，养成每次用药前复查的好习惯。确实无法解决的任何用药问题，都建议第一时间咨询有资质的医生或药师。\u003Cbr>有了这些关键细节，相信大家能更安心地用好每一种药品。\n    \u003C/p>\n  \u003C/div>\n  \u003Cdiv class=\"lcg2-ref-area\">\n    \u003Ch4 class=\"lcg2-ref-title\">参考文献\u003C/h4>\n    \u003Col class=\"lcg2-ref-list\">\n      \u003Cli>Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., et al. (2005). Erlotinib in previously treated non–small-cell lung cancer. \u003Cem>Journal of Clinical Oncology, 23\u003C/em>(25), 5892-5899. https://doi.org/10.1200/JCO.2004.19.1176\u003C/li>\n      \u003Cli>Gettinger, S., Horn, L., Jackman, D., et al. (2016). Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study. \u003Cem>Lancet Oncology, 17\u003C/em>(12), 1538-1548. https://doi.org/10.1016/S1470-2045(16)30400-3\u003C/li>\n      \u003Cli>Lacouture, M. E., Anadkat, M. J., Jatoi, A., et al. (2009). Dermatologic toxicities associated with anticancer agents in the epidermal growth factor receptor inhibitor class: A systematic review. \u003Cem>The Oncologist, 14\u003C/em>(2), 123-140. https://doi.org/10.1634/theoncologist.2008-0206\u003C/li>\n    \u003C/ol>\n  \u003C/div>\n\u003C/div>\n\u003Cstyle>\n/* 全局样式，仅作用于本组件，避免污染外部 */\n.lcg2-materials-outer {\n  background: #f6f8fa;\n  max-width: 820px;\n  margin: 32px auto;\n  padding: 26px 24px 36px 24px;\n  border-radius: 22px;\n  box-shadow: 0 4px 22px 0 rgba(16,28,41,0.06);\n  font-family: 'PingFang SC', 'Helvetica Neue', Helvetica, 'Segoe UI', Arial, 'Microsoft YaHei', sans-serif;\n  font-size: 20px;\n  color: #3a3a40;\n  line-height: 1.9;\n}\n.lcg2-title-main {\n  color: #146da2;\n  font-size: 2.1em;\n  font-weight: 700;\n  text-align: center;\n  line-height: 1.4;\n  margin-bottom: 24px;\n  letter-spacing: 1px;\n}\n.lcg2-subtitle-bg {\n  background: linear-gradient(90deg,#d0efff 0%,#f8fafb 100%);\n  border-radius: 13px;\n  padding: 8px 0 8px 36px;\n  margin: 32px 0 16px 0;\n}\n.lcg2-subtitle {\n  color: #2193b0;\n  font-size: 1.35em;\n  font-weight: 600;\n  margin-bottom: 0;\n  letter-spacing: .5px;\n}\n.lcg2-section {\n  margin-bottom: 18px;\n  padding: 8px 14px 8px 18px;\n  background: #fff;\n  border-radius: 12px;\n  border: 1px solid #e0e9f0;\n}\n.lcg2-list {\n  margin: 10px 0 10px 24px;\n  padding-left: 0;\n  list-style-type: disc;\n  color: #295079;\n  font-size: 0.98em;\n}\n.lcg2-highlight {\n  color: #e86b4d;\n  font-weight: 600;\n  margin-right: 6px;\n}\n.lcg2-cite {\n  font-size:0.88em;\n  color: #55728e;\n  margin-left: 6px;\n}\n.lcg2-summary {\n  margin: 36px 8px 18px 8px;\n  background: linear-gradient(90deg,#e5f4ec 0%, #fdfbfa 100%);\n  border-radius: 14px;\n  padding: 24px 22px 16px 28px;\n  border: 1px solid #dedede;\n}\n.lcg2-summary-title{\n  color:#19835b;\n  font-weight:700;\n  font-size: 1.15em;\n  margin-bottom:10px;\n}\n.lcg2-summary-highlight{\n  color:#d0384e;\n  font-weight:600;\n  padding:0 2px;\n  background: #fff4f2;\n  border-radius: 4px;\n}\n.lcg2-ref-area {\n  background: #f4fafb;\n  border-radius: 13px;\n  padding: 18px 24px 16px 36px;\n  margin-top: 38px;\n  border: 1px solid #d3e8f4;\n}\n.lcg2-ref-title {\n  color: #2470b5;\n  font-weight:600;\n  font-size:1.12em;\n  margin-bottom: 10px;\n}\n.lcg2-ref-list {\n  color: #2c3a4b;\n  font-size: 0.93em;\n  padding-left: 18px;\n  margin: 0;\n}\n.lcg2-ref-list li {\n  margin-bottom: 7px;\n  line-height: 1.7;\n}\n@media (max-width: 700px){\n  .lcg2-materials-outer {\n    padding: 14px 2vw 20px 2vw;\n    font-size: 17px;\n  }\n  .lcg2-title-main { font-size: 1.2em;}\n  .lcg2-ref-area { padding-left: 15px; padding-right: 6px;}\n}\n\u003C/style>","\u003Cdiv class=\"lcg2-materials-outer\">\n  \u003Ch1 id=\"material_title\" class=\"lcg2-title-main\">\n    肺癌IIIB期常用药",550,"2025-10-23 19:32:53","肺癌IIIB期, 化疗药物, 靶向药物, 免疫检查点抑制剂, 安全用药","了解肺癌IIIB期治疗的常用药品及用药细节，确保安全有效。涵盖化疗、靶向及免疫治疗的关键要点，帮助患者及家属应对用药挑战。","2025-11-09 17:30:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]